ANGPTL2 Research Using The IBL Assay Linked To The Progression Of Heart Failure
Posted by Brandon Savela on Mar 30th 2017
New studies using our Angiopoietin-like proteins Assay kit.
A cardioprotective response that alters ventricular contractility or promotes cardiomyocyte enlargement occurs with increased workload in conditions such as hypertension. When that response is excessive, pathological cardiac remodelling occurs, which can progress to heart failure, a leading cause of death worldwide. Mechanisms underlying this response are not fully understood. Here, we report that expression of angiopoietin-like protein 2 (ANGPTL2) increases in pathologically-remodeled hearts of mice and humans, while decreased cardiac ANGPTL2 expression occurs in physiological cardiac remodelling induced by endurance training in mice. Mice overexpressing ANGPTL2 in heart show cardiac dysfunction caused by both inactivation of AKT and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)2a signalling and decreased myocardial energy metabolism. Conversely, Angptl2 knockout mice exhibit increased left ventricular contractility and upregulated AKT-SERCA2a signalling and energy metabolism. Finally, ANGPTL2-knockdown in mice subjected to pressure overload ameliorates cardiac dysfunction. Overall, these studies suggest that therapeutic ANGPTL2 suppression could antagonize development of heart failure.
ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients. Gellen B et al. Diabetologia. 2016 Nov;59(11):2321-30.
PMID:27491833
A high serum angiopoietin-like 2 (ANGPTL2) concentration is an independent risk factor for developing diabetes and is associated with insulin resistance and atherosclerosis. In this work, we have examined the impact of serum ANGPTL2 on improving cardiovascular (CV) risk stratification in subjects with type 2 diabetes.
As above two new insights, it has been revealed that Angptl2 is a risk factor of chronic inflammation and insulin resistance and it involves with progression of heart failure so that it has been expected that Angptl2 can be a candidate for the target of development of new drug and functional materials.
It has been revealed that Angptl2 is a risk factor of chronic inflammation and insulin resistance.
The ANGPTL2 ELISA is For Research Use Only – Not for Use in Clinical Procedures.